Clinical Trial Update: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial comparing intravenous versus oral 5-HT3 antagonists combined with NK-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• 5-HT3 antagonist (intravenous) (5-HT3 antagonist)
• 5-HT3 antagonist (oral) (5-HT3 antagonist)
• NK-1 receptor antagonist (neurokinin-1 receptor antagonist)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Breast Cancer, Chemotherapy-induced Nausea and Vomiting | Phase 4 | Status: NOT_YET_RECRUITING